Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) controlled unit Fosun Pharma Industry started the Phase Two clinical trial in China for FXS7553, targeting chronic obstructive pulmonary disease (COPD), according to a Thursday aftermarket filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai and Hong Kong bourses.